商务合作
动脉网APP
可切换为仅中文
by GOAI
由GOAI生成
Share To
分享到
Sobi has entered into an agreement to acquire Arthrosi Therapeutics, a biotechnology company based in the United States, for $950 million. The deal aims to bolster Sobi’s pipeline of treatments for gout, a form of inflammatory arthritis caused by elevated levels of uric acid in the blood.
Sobi 已达成协议,将以 9.5 亿美元收购总部位于美国的生物技术公司 Arthrosi Therapeutics。该交易旨在加强 Sobi 的痛风治疗管线,痛风是一种因血液中尿酸水平升高引起的炎症性关节炎。
Arthrosi Therapeutics specializes in developing therapies targeting chronic diseases, including gout. The acquisition is expected to provide Sobi with access to Arthrosi’s innovative drug candidates and research capabilities. This move aligns with Sobi’s strategy to expand its portfolio in areas of unmet medical need.
Arthrosi Therapeutics 专注于开发针对慢性疾病(包括痛风)的疗法。此次收购预计将使 Sobi 获得 Arthrosi 的创新药物候选产品和研发能力。这一举措符合 Sobi 扩大在未满足医疗需求领域产品组合的战略。
Details regarding the timeline for completion or integration plans have not been disclosed at this time..
目前尚未披露有关完成或整合计划的时间表的细节。
Newsflash | Powered by GeneOnline AI
新闻快讯 | 由GeneOnline AI提供支持
Source: GO-AI-ne1
来源:GO-AI-ne1
For any suggestion and feedback, please contact us.
如有任何建议和反馈,请联系我们。
Date: December 15, 2025
日期:2025年12月15日
Related posts:
相关文章:
New Software Interface Boosts Task Completion by 15%
新软件界面使任务完成率提升15%
Experts Discuss Upcoming Hot Line Trials on Heart Failure and Drug Therapies at ESC Congress 2025
专家在2025年ESC大会上讨论即将进行的心力衰竭和药物治疗的热门试验
Emergency Medicaid for Undocumented Immigrants Comprised Less Than 1 Percent of State Medicaid Spending in 2022
2022年,无证移民的紧急医疗补助占州医疗补助支出的比例不到1%。
Exosomes Linked to Bortezomib Response in Multiple Myeloma Through Ketotifen and Redox Signaling
通过酮替芬和氧化还原信号传导,外泌体与多发性骨髓瘤中硼替佐米反应相关
©www.geneonline.com All rights reserved. Collaborate with us:
©www.geneonline.com 保留所有权利。与我们合作:
[email protected]
电子邮件地址
Author
作者
GOAI
GOAI
Related Post
相关文章
News Flash
新闻快讯
Study Compares ChatGPT’s Empathy Responses to Those of Human Physicians in Healthcare Scenarios
研究比较了ChatGPT在医疗场景中与人类医生的同理心回应
2025-12-15
2025年12月15日